Is one of your patients the key to advancing treatment options for those living with narcolepsy?

Avadel is seeking patients suffering from narcolepsy with cataplexy to enroll in the REST-ON trial, a Phase III clinical trial evaluating investigational once-nightly sodium oxybate.

The REST-ON (Randomized study Evaluating the efficacy and SafeTy of a Once Nightly formulation of sodium oxybate) trial is a double-blind, randomized, placebo-controlled, two-arm, multicenter, Phase III clinical trial evaluating FT218, an investigational extended-release oral suspension of sodium oxybate. This trial will assess the safety and efficacy of investigational once-nightly sodium oxybate for the treatment of excessive daytime sleepiness, with or without cataplexy, in patients with narcolepsy.

Enrollment is open for patients aged 16 years or older with a current diagnosis of narcolepsy with cataplexy. Trial sites are available in the US, Canada, UK, Germany, France, Czech Republic, Finland, Denmark, Australia, the Netherlands, and Switzerland.

Your patients may be eligible to participate in the REST-ON trial if they:

  • Have narcolepsy WITH cataplexy
  • Are 16 years of age or older
  • Have never been treated with sodium oxybate or have had very limited prior use*
*Additional eligibility criteria applies

If you have patients who may meet these eligibility requirements, or know another physician with patients who may, please let them know about our important study. Enter your information and we’ll send you additional details about the trial, including eligibility criteria and further information for potential patient referral.